HS-1371

Be the first to review this product! Submit a review

|

(0 Publication)

MW 384.5 Da, Purity >98%. Potent RIP3 kinase inhibitor (IC₅₀ = 20.8 nM). It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro. It inhibits TNF-induced necroptosis but does not inhibit TNF-induced apoptosis, indicating that HS-1371 has a specific inhibitory effect on RIP3-mediated necroptosis via the suppression of RIP3 kinase activity.

View Alternative Names

ACTR-IB, ACV1B_HUMAN, ACVR 1B, ACVRLK 4, ALK tyrosine kinase receptor, ALK-4, ALK/EML4 fusion gene, included, ALK/NPM1 fusion gene, included, ALK_HUMAN, AUTS9, Activin A receptor type 1B, Activin A receptor type II like kinase 4, Activin A type 1B receptor, Activin A type IB receptor, Activin receptor type IB, Activin receptor type-1B, Activin receptor-like kinase 4, Anaplastic lymphoma kinase, Anaplastic lymphoma kinase Ki1, Angiopoietin-1 receptor, BFGFR, Basic fibroblast growth factor receptor 1, CD 246, CD202b, CD202b antigen, CD246 antigen, CD309, CD309 antigen, CD331, CEK, D249, EC 2.7.10.1, Eag-related protein 1, Endothelial tyrosine kinase, Endothelium specific receptor tyrosine kinase 2, Ether a go go related potassium channel protein, Ether-a-go-go-related gene potassium channel 1, Ether-a-go-go-related protein 1, FGFBR, FGFR1/PLAG1 fusion, FGFR1_HUMAN, FLFL2, FLG, FLJ31474, FLK-1, FLK1, mouse, homolog of, FLT-2, Fetal liver kinase 1, Fms-like gene, Fms-like tyrosine kinase 2, H-ERG, HBGFR, HGF receptor, HGF/SF receptor, HGFR, HH2, HRTFDS, Hepatocyte growth factor receptor, Hyk, KAL2, KCNH2_HUMAN, KI 1, KIAA1387, KRD1, Kdr, Kinase insert domain receptor, Kinase insert domain receptor (a type III receptor tyrosine kinase), Kv11.1, LQT 2, LTK_HUMAN, Leukocyte receptor tyrosine kinase, Leukocyte tyrosine kinase, Leukocyte tyrosine kinase receptor, Ly73, MET proto oncogene, receptor tyrosine kinase, MET_HUMAN, Met proto oncogene tyrosine kinase, Met proto-oncogene, Met proto-oncogene (hepatocyte growth factor receptor), N-SAM, NBLST 3, OGD, Oncogene MET, PP4R3 beta, PP4R3B, PPP4R3 Beta, PPP4R3B, PSY2, Potassium channel HERG, Potassium voltage gated channel subfamily H (eag related) member 2, Potassium voltage-gated channel subfamily H member 2, Protein Phosphatase 4, Regulatory Subunit 3 Beta,, Protein tyrosine kinase 1, Protein-tyrosine kinase receptor flk-1, Proto-oncogene c-Fgr, Proto-oncogene c-Met, RCCP2, SF receptor, SKR 2, SMEK homolog 2, SMEK homolog 2 suppressor of mek1, SMEK homolog 2 suppressor of mek1 (Dictyostelium), SQT1, Scatter factor receptor, Serine(threonine) protein kinase receptor R2, Serine/threonine-protein kinase receptor R2, Serine/threonine-protein phosphatase 4 regulatory subunit 3B, Soluble TIE2 variant 1, Soluble TIE2 variant 2, TCRZ, TEK tyrosine kinase endothelial, TFG/ALK, TIE2_HUMAN, TYK 1, Tek, Tunica interna endothelial cell kinase, Tyrosine kinase growth factor receptor, Tyrosine kinase with Ig and EGF homology domains-2, Tyrosine-protein kinase Met, Tyrosine-protein kinase receptor TEK, Tyrosine-protein kinase receptor TIE-2, VEGFR, VEGFR-2, VGFR2_HUMAN, VMCM, VMCM 1, Vascular endothelial growth factor receptor 2, Venous malformations multiple cutaneous and mucosal, Voltage gated potassium channel, subfamily H, member 2, Voltage-gated potassium channel subunit Kv11.1, anaplastic lymphoma kinase (Ki-1), anaplastic lymphoma receptor tyrosine kinase, bFGF-R-1, c met, eag homolog, fibroblast growth factor receptor 1, fms-related tyrosine kinase 2, hERG-1, hTIE 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, mutant anaplastic lymphoma kinase, p140 TEK, smk1, soluble VEGFR2, tek tyrosine kinase